Medication Safety & Prescribing

DetectRx is the drug diversion counterpart to Haystack iS, the iatricSystems patient privacy product already indexed here, and is recorded separately under the same product scoping rule. Released in May 2022 by iatricSystems of Ponce Inlet, Florida, a healthcare technology company with more than three decades of integration work behind it, it evaluates dosing activity in near real time using what the company describes plainly as machine learning combined with expert written rules. The signal set is the most clinically interesting in this lane. Alongside the usual medication and reconciliation patterns and off shift or off location behaviour, DetectRx analyses patient pain scores. That is a genuinely different idea from anything else graded here. Every other product in this category reasons about the diverter; pain scores reason about the patient left behind, on the logic that a withheld dose shows up as pain that never resolves. Nobody else in this lane names it. The product draws from three system classes, the electronic health record, automated dispensing cabinets and timekeeping, and presents events risk ranked in a management dashboard. The second distinctive component is AVA, the Advanced Virtual Assistant shared with the privacy product. AVA triggers alerts, requests information and tracks responses against predefined parameters, and the company states the product responds automatically according to customised settings. In the sibling privacy record, AVA is documented as initiating a questionnaire directly with the user whose access was flagged, before a human has reviewed the case. Whether DetectRx does the same to a clinician suspected of drug theft is not stated in any published material located here, and it is the single most consequential open question about this product. The two situations are not equivalent. Being asked to explain a record you opened is an inconvenience; being contacted by an automated system about suspected controlled substance theft, before any person has looked at the case, is something else. The deployment evidence is named and checkable. Renown Health in northern Nevada implemented DetectRx in 2024, with its director of accreditation and regulation and its vice president of quality and patient safety both quoted, and reports moving from five risk factors monitored through manual monthly reports to twenty four monitored through the product. Peterson Health is named through its director of pharmacy. Worth reading carefully: twenty four risk factors is a measure of how much is now watched, not of how much was caught, and no detection rate, accuracy figure or case outcome has been published.

Imprivata Drug Diversion Intelligence, sold as DDI and previously carrying the Imprivata FairWarning name, is the diversion monitoring counterpart to the Patient Privacy Intelligence product already indexed here. It is recorded separately under the same product scoping rule that governs that entry: Imprivata's wider business is healthcare identity and access management, which would not qualify on AI centrality, and this record covers the diversion product specifically. Both products descend from the FairWarning and Maize Analytics acquisitions and now sit inside the Imprivata Digital Identity Framework under access compliance. The product monitors the controlled substance lifecycle from prescription through dispensing, preparation, administration, waste and removal, using machine learning to establish baseline behaviour for medication access and flag deviation from it, including peer comparison and out of hours activity. It ships more than 250 report types for compliance and audit, an investigation platform, and an optional monitoring services team. It has been sold in the United States for years and became available in Canada in March 2023. One named technical capability is unlike anything else in this lane. OneRx is described as AI assisted technology that standardises medication names across disparate source systems. Inconsistent drug naming between the electronic health record, the dispensing cabinet and the pharmacy system is a mundane and genuinely destructive problem for this category, because a reconciliation engine cannot match what it cannot recognise, and this is the only vendor here that names the problem and ships something specific at it rather than treating clean input as a given. The security and privacy position is the strongest in this lane. Imprivata holds ISO 27001 and ISO 27701 certifications issued by A LIGN, maintains a public trust and security page, and states a SOC 2 attestation alongside HIPAA governance. ISO 27701 is the privacy information management standard and is rare across this entire index, which matters for a product whose subject is the behaviour of named staff. Two things a buyer should confirm rather than assume: the certification announcement cites the 2013 revision of ISO 27001, which has since been superseded, so the transition to the current revision should be verified, and the published scope is described at company level without enumerating which products fall inside it. The weakness is evidence. No outcome study, accuracy figure or named customer result was located. The only checkable third party measure found is a KLAS assessment reported in 2022 that scored Imprivata 70.1 in drug diversion monitoring, the lowest of the four vendors covered in that report and flagged there as resting on limited data. That figure is four years old and should not be treated as current, but nothing published since replaces it.

ANiGENT sells one thing, drug diversion detection, through one platform called MAAP Analytics, short for Medication Administration and Analysis Program. It was established in 2019 in St. Louis to commercialise software that had already run for years inside a hospital, and launched publicly in March 2020 as a venture between DYNALABS, an analytical laboratory testing business, and Mayo Clinic. Omnicell acquired the company in October 2025. The brand, the site and the product name all remain in use, with ANiGENT's own material describing it as now part of Omnicell, so it is indexed here under its own name with the parent recorded, and the separate Omnicell record covers the dispensing estate. The platform is built from modules: AUDITOR for reconciliation, Waste Reconciliation and Assay, Peer to Peer Behavioral Analysis, and INSIGHTS, with dashboards delivered through Microsoft Power BI. The company describes the method as a blend of applied human logic and advanced machine learning drawing on five data sources, which is a more honest formulation than most in this lane, since it concedes that rules do part of the work. Its stated technical differentiator is breadth of process modelling: where competitors track a one to one relationship between dispense and administration, MAAP claims to chart more than 300,000 combinations of how a medication can be handled in a hospital, which is what allows it to separate a practice error from a theft. The DYNALABS parentage produces a capability nothing else in this category has. Waste Reconciliation and Assay pairs software surveillance with actual laboratory testing of returned waste, so a hospital can establish whether the substance in the container was the drug it was recorded as. Every other vendor here reasons from transaction records alone about a physical event they cannot observe. Two claims need to be read carefully and both are the company's own. The first is that MAAP Analytics 3.0 enables near 100 percent accuracy in identifying the true cause of a variance, described as the first product in the market to do so, with no definition of accuracy, no population and no method given. The second is more consequential: the Peer to Peer module is said to predict, within minutes, which specific users will divert medications at particular locations and times. That is a claim to identify named employees before they have done anything, and nothing published describes what a customer is expected to do with such a prediction, what threshold produces it, or what protects the person it names. The evidence base is a five year benchmark study at Mayo Clinic Arizona, reporting practice inefficiencies reduced to under one percent and more than $3 million recouped over five years, with more than 80 facilities on the platform as of 2022. That study is the flagship validation and Mayo Clinic co founded the company, so it is a related party evaluation and should be weighed as one. It also measures revenue recapture and practice efficiency rather than diversion detection accuracy, which is a different question from the one the product is sold on.

Sentri7 Drug Diversion is the diversion detection module of Wolters Kluwer Health's Sentri7 clinical surveillance platform. Wolters Kluwer is a global information and software business reporting revenues of 5.9 billion euros for 2024 across healthcare, tax, accounting, legal and corporate compliance, far too broad to grade on these axes, so this record covers the product and notes the parent. The index already applies the same treatment to UpToDate. The technology is the former Flowlytics platform, built by Invistics of Atlanta and acquired by Wolters Kluwer Health in June 2023 into its Clinical Surveillance, Compliance and Data Solutions unit. The Invistics brand was retired on absorption and is not separately indexed. Sibling modules on the same platform cover pharmacy surveillance and infection control, which took Best in KLAS rankings announced in February 2026, and those awards belong to the siblings rather than to the diversion module graded here. What distinguishes this record is that the central claim has been tested and published. A study in the American Journal of Health-System Pharmacy, funded by the National Institutes of Health, evaluated the software across ten acute care inpatient hospitals in four health systems, covering more than 20,000 clinicians and over 25 million medication movement transactions. It reported detection of all 22 known diversion incidents, accuracy of 96.3 percent, specificity of 95.9 percent and sensitivity of 96.6 percent, and detection of known cases a mean of 160 days and a median of 74 days earlier than the incumbent methods. Two qualifications belong with those figures. The study evaluates the vendor's own product, so a reader should check the authorship and funding declarations rather than take independence for granted. And it was conducted on the software as Invistics ran it, before the acquisition and before whatever has changed since. The product reconciles transactions across more than seven named data sources, including the electronic health record, automated dispensing cabinets, CII Safe, the narcotics vault, reverse distributors, retail pharmacy systems, wholesaler systems and the employee time clock, and weighs more than 60 determinants of risk. It covers non controlled medications as well as controlled ones, which most of this category does not, and spans pharmacy, nursing, anaesthesia and the supply chain either side of the hospital. The shape of this record is unusual and worth stating plainly. On what the model does and how well it works, this is the most transparent vendor in the lane by a wide margin. On how the product is secured, hosted, governed and what recourse exists when it is wrong, it is among the least. Those are the two halves of the same buyer's question and only one of them has been answered.

This record covers BD's medication dispensing estate as sold to hospital pharmacy: the BD Pyxis family of automated dispensing systems and the BD HealthSight analytics layer that runs on top of it. Becton Dickinson as a whole is far too broad to grade on these axes, spanning syringes, catheters, surgical instrumentation and much else, so the parent is noted here rather than indexed. BD's own securities filings draw the same boundary this record does, separating the Dispensing quality management system from the Infusion quality management system that governs BD Alaris. Alaris sits outside this record. The hardware is the Pyxis ES portfolio: MedStation ES dispensing cabinets with CUBIE pocket technology, Anesthesia Station ES for the operating room, MedBank countertop and restricted access stations for controlled substances and temperature sensitive stock, supply dispensing cabinets, and Med Link Queue and Waste for witnessed disposal. It reached BD through the $12 billion CareFusion acquisition in 2015 and is still manufactured by CareFusion 303, Inc. in San Diego. The intelligence sits in BD HealthSight. Diversion Management is the substantive machine learning product. It draws on dispensing behaviour and the electronic medical record, compares an individual clinician against a dynamically selected peer group within the facility, produces an individual risk score, and names the behaviours that contributed to it, including overrides, cancelled transactions, and delays in dispensing, administering and wasting medication. It automates controlled substance reconciliation, flags discrepancies, and routes cases into an investigation workflow with assignment to named investigators. Inventory Optimization and the HealthSight Viewer complete the layer. Two things make this record unusual and both belong in front of a buyer. The mechanism description is more specific than anything else in this lane, naming the signals and the comparison population rather than stopping at the phrase predictive analytics. And the regulatory and security record is documented in extraordinary detail, because securities law and coordinated vulnerability disclosure compelled it. A November 2024 FDA Warning Letter cites the dispensing quality system, and BD carried a $68 million liability for the response as of March 2026. Five cybersecurity advisories reached the Cybersecurity and Infrastructure Security Agency between 2018 and 2022. None of that is concealed, and a buyer here has more primary source material to work with than for any comparable product. What that material says is a separate question from how completely it is available, and the grades below keep the two apart.

Omnicell sells the physical infrastructure of hospital medication management and has spent the past six years attaching an intelligence layer to it. The hardware came first and still carries the business: XT automated dispensing cabinets at the point of care, XR2 robotics in the central pharmacy, IV compounding systems, and supply cabinets, sold into acute hospitals, health systems, retail and specialty pharmacies, long term care and residential settings, in the United States and internationally. The software sits on top of that installed base. OmniCenter is the established on premise platform. OmniSphere, introduced at the end of 2024, is the cloud native workflow engine and data platform intended to succeed it, running on Amazon Web Services and sold on enterprise wide visibility and interoperability with the electronic health record. Omnicell One, generally available since August 2020, is the predictive layer over pharmacy inventory. Omnicell Analytics targets drug diversion. Titan XT is the next generation cabinet, which the company reported in April 2026 was entering health system capital planning cycles. In October 2025 Omnicell acquired ANiGENT, a St. Louis software company whose MAAP Analytics platform does machine learning driven drug diversion detection and originated at Mayo Clinic. ANiGENT continues to trade under its own name with its own site and product, so it is indexed separately in this category rather than folded in here. Anyone assessing Omnicell's position in diversion surveillance should read both records together, and should note that Omnicell's HITRUST certification scope enumerates specific Omnicell products and does not name MAAP Analytics. The company frames all of this as the Autonomous Pharmacy, and its own securities filing describes the business as empowering autonomous medication management. Read closely, the same passage commits to equipping pharmacists and nurses to focus on patient care rather than administrative tasks, which is a narrower claim than the brand implies and a more accurate one. The autonomy on offer is the removal of counting, stocking and reconciling, not of clinical judgement. Omnicell is a public company, founded in 1992, headquartered in Fort Worth, Texas and listed on Nasdaq as OMCL, with an engineering innovation lab opened in Austin in 2025. Its scale is documented in filings rather than asserted in marketing, which is unusual in this index and matters for how the grades below should be read. The low AI centrality grade describes what the models built inside this business do. It is not a judgement on the size, maturity or quality of the business itself, which is among the largest in the category.

Surescripts is the network almost every other vendor in this lane routes across, and it should be read directly against the DrFirst record built alongside it. Both companies attack the same problem, the unstructured sig instruction, and they attack it from opposite positions: DrFirst as a participant enhancing data after it arrives, Surescripts as the network enhancing it in transit. The scale is the defining fact. Healthcare professionals exchanged 30.5 billion transactions through the Surescripts Network Alliance in 2025. The company connects electronic health record vendors, pharmacies, pharmacy benefit managers, health plans, health systems, long term and post acute care, specialty pharmacies, life sciences companies and analytics vendors, and its product set runs from electronic prescribing and controlled substance prescribing through medication history, eligibility, formulary, real time prescription benefit, electronic prior authorisation and prescription transfer. Sig IQ is the machine learning product and it does the same job as DrFirst's SmartSig. It translates free text patient directions into the Structured and Codified Sig format, a standardised structure that removes ambiguity, and the company describes it as catching confusing or potentially dangerous sigs before they reach patients. Two design details distinguish it. It is anchored to the NCPDP industry standard rather than a proprietary schema, and the company states it uses a pharmacist review process alongside the model. Introduced for medication history in 2022 and extended to prescribing transactions in late 2023, it delivered 4.1 billion structured sigs in 2024 against 1.9 billion the year before, and augmented more than two million renewal transactions in its first six months on that pathway. Artificial intelligence appears elsewhere in the network and the company enumerates where, which is unusual. A semantic network underpins the workflow engine in the electronic prior authorisation portal. Record Locator and Exchange and the Specialty Medications Gateway use models to break down clinical document architectures and identify unique clinical attributes. And the company discloses a development detail most vendors would omit: it used artificial intelligence to parse text sigs, and that work informed the machine learning techniques built into Sig IQ. In August 2024 it published a formal artificial intelligence commitment under four named principles, ethical use, privacy and security, transparency, and accountability, with the ethical use principle explicitly naming potential biases and the accountability principle committing to prioritise appropriate human oversight. A named chief data and analytics officer, a physician, publishes on keeping humans in the loop. Formed in 2008 through the merger of SureScripts and RxHub, both founded in 2001 by pharmacy and pharmacy benefit trade organisations respectively. Based in Arlington, Virginia, led by chief executive Frank Harvey, and publishing an annual impact report.

DrFirst fills the gap this lane had. The seventeen records already here are clinical decision support and pharmacokinetics: interaction checking, dosing models, adherence prediction. All of them assume the medication data arriving in the chart is usable. DrFirst works on the assumption itself, and its central claim is that the assumption is false. The problem is the sig, the shorthand prescribing instruction carrying dose, route and timing. When medication history is imported into an electronic health record it arrives as unstructured free text, frequently incomplete, and written in whatever synonym the source system used, by mouth against orally against PO. The company states that an estimated 66 percent of records in the largest national medication history database are missing essential sig information. Data in that condition cannot trigger the interaction and allergy checks the record system is capable of running, so the safety machinery every other vendor in this lane depends on is silently disarmed. SmartSig is the patented artificial intelligence that addresses it, converting free text into discrete sig components, codifying them into each facility's standard terminology, and supplying alternative drug identifiers for best case matching where a medication cannot be resolved. It sits inside MedHx, the medication history product, and both now sit inside Fuzion, an enterprise platform launched in 2023 that the company describes as running on clinical grade artificial intelligence. The deployment evidence is the strongest thing on this record and several institutions publish it themselves. Hackensack Meridian Health reports that automatic sig mapping rose from 26 percent to 86 percent across a sample of 300,000 medications. Scripps reports medication history available for 96 percent of patients over 65 with 85 percent of home medication sigs enhanced. Monument Health reports 93 and 82 percent on the same measures. Covenant HealthCare reported recapturing 15 percent productivity per shift in the first month, which it valued at roughly $650,000 a month. Emory Healthcare reports a 13 percent improvement in best possible medication history. Around the medication history work sits a much larger business: electronic prescribing through Rcopia and iPrescribe, controlled substance prescribing, secure clinical messaging through Backline, benefits checking and adherence. The 2024 acquisition of Myndshft extended prior authorisation from pharmacy benefit into medical benefit, covering eligibility for 95 percent of insured patients and authorisation requirements for more than 600 payers. Founded in 2000 by James F. Chen and based in Rockville, Maryland, with recent announcements datelined Arlington, Virginia. Roughly 459 employees and $135M raised across eight rounds. G. Cameron Deemer joined in 2004 and led the company as chief executive for two decades, and sources disagree on whether he still holds the role following a July 2025 announcement referring to him continuing as vice chairman of the board.

RxAnte predicts which health plan members will stop taking their medication, and then sells the plan a way to intervene. It is a portfolio company of UPMC Enterprises, the venture arm of the health system, and its president is Aaron McKethan. The analytics come first. Predictive models identify members who are already non adherent and, more usefully, those likely to become so while there is still time to act, scored against the Medicare Star Ratings medication measures, HEDIS measures and patient experience surveys. The company states its analytics cover more than 14 million lives and that it manages Part D star performance for 70 percent of the lives in five star Medicare Advantage prescription drug plans nationally. The targeting criterion is named openly in the product itself. The Value of Future Adherence score, produced by the company's VFA software, identifies members with the greatest cost savings potential, and the company describes it as letting a plan engineer the return on its pharmacy care management programme. Members are ranked by what their non adherence would cost, not by how sick they are. Since 2019 the company has also owned the intervention. Mosaic Pharmacy Service is a working pharmacy for medically complex Medicare members on multiple chronic medications: a virtual visit and enrolment offer, a pharmacist medication review using its Therapeutic Decision Support tool, 30 day supplies delivered in pre sorted pouches including over the counter items, and monthly follow up with prescribers and caregivers. The company has published a matched control analysis of Mosaic within a Medicare Advantage plan, comparing enrollees against members who filled prescriptions elsewhere on total cost of care, unplanned care events and adherence at six months, with a pre stated hypothesis that savings would be greatest in the high scoring subgroup. Named health plan relationships include Aetna and UPMC Health Plan, and its work has appeared in NEJM Catalyst.

FDB, formerly First Databank, supplies the drug knowledge that sits underneath most medication decisions made in the United States. Its databases are embedded in the majority of hospitals, physician practices and pharmacies, which means that when a prescribing system warns about an interaction, a dose ceiling or a contraindication, the content behind that warning is frequently this company's rather than the software vendor's. It is owned by Hearst and part of Hearst Health, the same group that owns Zynx Health. The asset is human curated: clinical editors maintain the content and the company's stated credibility rests on rigorous quality control and clinical expertise rather than on any model. What makes the record current rather than historical is a deliberate repositioning. In October 2025 FDB opened pilot integrations of a Model Context Protocol server, and on 31 March 2026 it made FDB MedProof MCP generally available, described as the first such server purpose built for agent driven medication decision support, letting other companies' AI agents and language models query clinically validated drug knowledge in patient specific context rather than answering from training data. Two further products were previewed in March 2026 and are not yet generally available: FDB Script Agent, which turns a spoken clinical conversation into a structured prescription for physician review, and FDB VerifyAssist, an inpatient pharmacy order verification assistant. The company is positioning itself as the grounding layer beneath other people's medication AI.

Genomind pairs a pharmacogenetic laboratory test with software that turns the result into prescribing guidance, with a centre of gravity in mental health. The assay is a clinician ordered buccal swab genotyped by quantitative PCR across 26 to 27 genes, split between 11 that affect how a drug is metabolised and 15 that affect how the body responds to it, returning results in three to five days and covering more than 700 medications. The Precision Health Platform then integrates that genotype with the patient's current medication list to flag gene to drug and drug to drug interactions and propose alternatives. The company was founded in King of Prussia, Pennsylvania by Dr Ronald Dozoretz, sells to individuals, prescribers, long term care facilities, accountable care organisations, employers and health plans, holds a contract supporting testing for United States active duty service members, and licenses its reporting suite to other laboratories so that its interpretation layer reaches patients whose samples it never handled. What distinguishes this record from everything else in the category is what the company did with its own evidence. It sponsored and co authored a multicentre randomised controlled trial of its own test in major depressive disorder, blinded to both participants and raters, and the trial found no significant improvement in the primary efficacy outcome. The company continues to cite that trial on its own science page.

TheraDoc is one of the two incumbent clinical surveillance platforms in American hospitals, monitoring live feeds of laboratory, microbiology, pharmacy and admission data to raise alerts for infection prevention, antimicrobial stewardship, pharmacy surveillance and anticoagulation management, and to produce mandatory infection reporting. It was founded in Salt Lake City in 1999, sold to Hospira, and acquired by Premier in 2014 for 117 million dollars in cash, and is now marketed as Premier's Clinical Surveillance powered by TheraDoc. Its mechanism is a rules engine rather than a model: pharmacists and infection preventionists author their own alert logic, and the system evaluates those written queries continuously against incoming data. Premier makes no artificial intelligence claim for the product on its own pages, which is more accurate than what its principal competitor publishes. The one genuine model inside the product is licensed rather than built, since Premier's own material states that the integrated precision vancomycin dosing tool in TheraDoc comes from InsightRX. Two ownership facts matter for procurement. Premier completed a 2.6 billion dollar take private by Patient Square Capital, having reported an eleven percent revenue decline in fiscal 2025 and having explored strategic alternatives since 2023. And Premier separately owns Stanson Health, so a single supplier now sits behind both this surveillance platform and a point of care decision support product.

VigiLanz is the other incumbent clinical surveillance platform in American hospitals and the direct competitor to TheraDoc. Founded in Minneapolis in 2001 by David Goldsteen and acquired by Inovalon in February 2024, it ingests near real time data from any electronic health record, including admission feeds, medication administration records, laboratory results, microbiology and medication history, across acute, post acute and ambulatory settings, and converts it into alerts for pharmacy surveillance, infection prevention, antimicrobial stewardship, quality improvement and patient safety event reporting. The mechanism is configurable rules, and the company's own product page describes it in a phrase worth quoting because it captures the entire problem this index exists to address: flexible, rule based AI. Independent product listings describe the same engine plainly as configurable and rule based. Alerts surface directly inside the electronic health record for faster acknowledgement, and the platform supports intravenous to oral conversion review, antibiogram trending and transitions of care. As with its competitor, the genuine model reaching clinicians through the product is licensed from elsewhere: Inovalon announced a collaboration in October 2025 bringing DoseMeRx precision dosing into these pharmacy surveillance workflows. The company cites eight consecutive years as the leading pharmacy surveillance solution in one analyst firm's rankings.

EndoTool is an FDA cleared inpatient insulin dosing system and the closest direct competitor to Glucommander, covering intravenous dosing, the transition from intravenous to subcutaneous insulin, and subcutaneous dosing for adult and paediatric patients. Its algorithm is described in independent literature as model predictive control using a nonlinear dosing equation that is individualised and then optimised over time against how that patient's glucose actually responded to the doses already given, drawing on diabetes type, height, weight, creatinine, age and sex. That is a more elaborate approach than the proportional control its main competitor uses, and it is still deterministic mathematics rather than machine learning: the same peer reviewed reviews that describe it group it with rule based systems carrying static decision rules rather than adaptive learning models. The product was built by Monarch Medical Technologies of Charlotte, North Carolina, which also appears in the clinical literature under the name MD Scientific LLC, and Glooko acquired Monarch in September 2025 to extend its outpatient diabetes platform into the hospital, describing the combination as a hospital to home continuum. Glooko has stated that both product lines continue to operate and be supported. The vendor characterises the algorithm as patented and patient specific, and markets against the same 2026 CMS glycemic quality measures its competitor does.

Glytec's Glucommander is the oldest and most widely deployed computerised insulin dosing system in American hospitals, cleared by the Food and Drug Administration as Class II software for intravenous insulin since 2006 and for subcutaneous insulin since 2010, in patients aged two and over. It sits inside the GlytecOne platform alongside surveillance, alerting and analytics, and the company reports use across more than 400 hospitals and health systems and dosing for over 867,000 patients since 2015. The mechanism deserves stating plainly because the marketing does not. Independent reviews describe Glucommander as a proportional integral derivative controller applying a linear formula derived from a 1982 paper, where the hourly insulin dose is a function of blood glucose above a floor multiplied by a factor that steps up until glucose reaches target. It adapts to the individual patient through that feedback loop, which is real closed loop control and is not machine learning, and the same reviews explicitly classify these systems as rule based with static decision rules rather than adaptive learning models. The company nonetheless describes the algorithm as learning each patient's insulin sensitivity. Distribution now extends to the bedside device itself through a partnership making Glucommander the first software application to run on Roche's cobas pulse hospital glucose meter, and the company markets heavily against a 2026 CMS glycemic quality mandate.

Synapse Medicine builds what it calls a medication intelligence platform, and the distinctive thing about it is where the machine learning sits. Rather than learning to make a prescribing recommendation, the company uses natural language processing to read and classify medication information from three kinds of unstructured source, manufacturer product documentation, official recommendations from health authorities, and published research, and to assemble that into a structured knowledge base that then drives interaction checking, prescription support and medication reconciliation. A separate product applies the same approach to pharmacovigilance itself, automating the coding and prioritisation of adverse drug reaction reports for the centres that receive them. The company was founded in Bordeaux in 2017 by Clement Goehrs and Louis Letinier, both physicians, with Bruno Thiao-Layel, and has raised roughly 39 million dollars across three rounds through a Series B in March 2022 led by Korelya Capital, with backing from a healthcare professionals' insurer and public investment banks rather than from pharmaceutical money. Its institutional position in France is unusual: users include the national medicines agency and the digital health agency alongside Assistance Publique Hopitaux de Paris, the Hospices Civils de Lyon and the Bordeaux teaching hospital, plus more than a hundred hospitals and dozens of telemedicine companies. The company states that it is completely independent of the pharmaceutical industry.

YouScript computes the cumulative effect of a patient's whole medication regimen together with their pharmacogenomic results, rather than checking drug pairs one at a time. Its founder, Kristine Ashcraft, makes the argument directly: American practice has relied on binary interaction alerting for decades, and binary alerting breaks down once a patient is on five or more medications, which now describes tens of millions of people. The patented engine models drug to drug interactions, drug to gene interactions and phenoconversion, where one drug alters how a patient metabolises another and effectively changes their genotype in practice, then returns severity coded guidance across four levels from change to no change alongside safer alternatives within the same drug class or indication. It draws on more than 19,000 high evidence references covering over 2,000 medications and integrates with Epic, Cerner, Allscripts and Telus Health as well as through standalone applications and APIs. The product was incubated for over a decade inside Genelex, a pharmacogenetic testing laboratory in Seattle, established as YouScript in 2016, acquired by Invitae in 2020, and sold to Aranscia in an all cash transaction announced in November 2023. It holds something rare in this category: a prospective randomised controlled trial with a rehospitalisation endpoint. It also markets itself as laboratory agnostic while having been owned by a testing business for essentially its entire existence.

Arine sells medication intelligence to health plans rather than to hospitals, which makes it the clearest payer side record in this category. The platform ingests clinical, socioeconomic and behavioural data across a plan's membership, identifies members at risk of medication related problems before they produce an event, generates personalised care plans for clinical pharmacists to act on, and separately analyses prescriber behaviour so a plan can direct education and recommendations at the clinicians writing the prescriptions. A third product line targets the Medicare Advantage and Part D quality measures, particularly the triple weighted adherence measures that carry disproportionate weight in the CMS Star Ratings that determine a plan's bonus payments. The company was founded in San Francisco by Yoona Kim, a doctor of pharmacy with a doctorate who serves as chief executive, alongside Penjit Moorhead as chief technology officer and David de Vries as chief operating officer, and it launched under the Arine name in 2019 after operating as Akeso. It has raised roughly 95 million dollars across six rounds through a Series C in June 2025, and holds a HITRUST risk based two year certification obtained in July 2024. Named clients span Medicaid, Medicare Advantage and behavioural health, including the Oklahoma Health Care Authority, Magellan Health, VNS Medicare and MDX Hawaii. Every outcome figure the company publishes is its own, though it names the analytic method behind them, which is more than most.

DoseMeRx is a Bayesian precision dosing platform for high risk parenteral medications, computing an individualised regimen from clinically validated pharmacokinetic models, patient characteristics, measured drug concentrations and, where available, genotype. It covers 42 drugs and reaches more than a thousand clinicians across more than a hundred locations spanning the United States, Europe, Asia Pacific, Africa and South America, which is the widest geographic footprint in this category. The product originated in Brisbane, Australia, and its corporate history is unusually eventful for software a hospital pharmacy depends on daily: Tabula Rasa HealthCare acquired it in a deal reported at up to 30 million dollars, completing in January 2019, and sold it four years later to an affiliate of Fairlong Capital on 20 January 2023, with customer contracts transferring to DoseMe Operations Inc. and Paul Edwards installed as chief executive. It now operates from Houston. Three owners in six years is a supplier continuity question a procurement committee should ask about directly rather than a criticism. What sets the record apart is disclosure. This is the only vendor in the category so far to publish where United States patient data physically resides, to state plainly that the customer owns the data it enters, and to describe in public the licence it takes back over de identified data for model improvement. It also holds HITRUST certification and claims to be the only Bayesian dosing platform that does.

PrecisePK is Bayesian therapeutic drug monitoring software from Healthware, Inc. in San Diego, and it has the longest continuous clinical lineage of any product in this category. It began as T.D.M.S. 2000, developed by Philip Anderson, a doctor of pharmacy, with pharmacokinetic consultants, and programmed by Anjum Gupta, a computer scientist, both professors at the University of California, San Diego, and beta tested by the Applied Pharmacokinetics Service at UCSD Medical Center and Rady Children's Hospital. It became a desktop product and later a web platform, and the company marks more than thirty years of partnership with UC San Diego Health across nine University of California sites. The software takes a patient's characteristics, laboratory results and dosing history, assigns them to a population pharmacokinetic model, and updates that model against measured serum concentrations to compute a regimen against an area under the curve, peak or trough target, with the Bayesian method able to work from a single randomly drawn level rather than requiring steady state trough sampling. It carries a genuine distinction: an independent group comparing five Bayesian dose optimising programs in critically ill patients found PrecisePK the least biased of the five. The company markets that result heavily, and a buyer should know the study included nineteen patients and also found this product among the harder ones to use. `founded` is left blank because the product lineage predates the current company branding and no founding year is published.

FeelBetter applies machine learning to polypharmacy, the problem of an older patient accumulating enough medications that the regimen itself becomes the hazard. The platform synthesises longitudinal pharmacy and clinical data across a whole population, identifies the patients at highest risk of near term deterioration or hospitalisation attributable to their medication regimen, recommends specific regimen changes to a clinical pharmacist, and monitors what happens after the intervention. It is organised as four tools: Insight for risk stratification, Navigator for workflow, Action for the pharmacist facing recommendation engine, and Impact for post intervention monitoring. The company was founded in 2018 by Liat Primor, previously VP of global portfolio and chief of staff at Teva Pharmaceuticals, and Yoram Hordan, and operates from Boston and Tel Aviv. It raised 5.9 million dollars in July 2023 bringing total funding to roughly 8 million, which is modest relative to the health systems it serves. Named customers span three distinct buyers: Atlantic Health System in New Jersey across its accountable care organisations, Americare in long term care, and Leumit Health Services, an Israeli health maintenance organisation. The evidence position is unusual for a company this size, since investigators at Brigham and Women's Hospital published a retrospective cohort of 108,817 patients in the American Journal of Managed Care evaluating the platform's recommendations. The company markets its approach under a coined term, Pharmaco-Clinical Intelligence, which describes a market position rather than a method, and almost no technical, security or compliance detail is published alongside it.

InsightRX builds model informed precision dosing software, which computes an individualised dose for a drug whose therapeutic window is narrow enough that getting it wrong causes harm. The core product, Nova, combines published population pharmacokinetic models with maximum a posteriori Bayesian forecasting: it starts from what is known about how a drug behaves in a population, updates that against the concentrations actually measured in this patient, and returns a regimen. A companion product, Apollo, aggregates the resulting data so an institution can examine dosing effectiveness across its own population. The company was founded in 2015 in San Francisco and its platforms are used by more than a hundred institutions and life science organisations across the United States and Europe, covering more than a hundred drugs and therapeutic areas including infectious disease, oncology and transplant. Vancomycin dominates the published record. What distinguishes InsightRX in this category is inspectability. The pharmacokinetic models it runs are named published models rather than proprietary ones, the company publishes which model it selects as default for which patients and the analysis behind that choice, and it has published its machine learning approach to model selection in a peer reviewed pharmacometrics journal. It is also one of the vendors whose software reaches clinicians through a competitor's product, since the precision vancomycin dosing tool inside Premier's TheraDoc clinical surveillance platform is InsightRX. The regulatory position deserves care from any buyer: the software carries a European CE mark obtained by self certification as a Class I device under the superseded Medical Devices Directive, and it holds no United States clearance of any kind.

NarxCare is a set of scores and visualisations layered on top of state Prescription Drug Monitoring Program data, built by Bamboo Health, formerly Appriss Health, which also supplies the underlying platform for more than 40 state and territory monitoring programmes. It is almost certainly the most widely deployed algorithmic risk score in American medicine, reaching hundreds of healthcare facilities and, by the company's account, five of the six largest pharmacy retailers. The report presents three Narx Scores covering narcotics, sedatives and stimulants, a set of configurable state indicators, and an Overdose Risk Score, a three digit value the company states is produced by a logistic regression model evaluating ten inputs drawn from dispensation history such as prescriber counts, pharmacy counts and morphine milligram equivalents over varying windows. Bamboo Health is explicit that the score does not predict whether a patient will experience an overdose, that it is a correlative summary against the histories of people who died of unintentional overdose, and that it must never be the sole justification for providing or refusing medication. The record here is unusual in the index because the company's security and compliance engineering is among the strongest of any vendor graded, while its algorithmic accountability is among the weakest, and the gap between those two is a choice about what to publish rather than a failure of capability. Peer reviewed informatics literature records that the score has been validated only on a subset of three states, has never been evaluated clinically, and has no published subgroup analysis, and in 2025 clinicians petitioned the Food and Drug Administration to determine whether it is a regulated device at all.

MedAware is an Israeli company whose platform monitors prescribing for medication related risk using machine learning rather than the rule libraries that conventional medication decision support runs on. It was founded in 2012 after a nine year old asthma patient died because his physician selected the wrong drug from an electronic prescribing dropdown, an error no interaction rule was written to catch because the prescription was internally consistent and simply belonged to the wrong patient. The engine applies outlier detection over longitudinal and real time patient data, an approach the company compares to fraud detection in financial services, and flags prescriptions that are anomalous for this particular patient rather than prescriptions that violate a predefined rule. Products span prescribing error detection, evolving adverse drug event monitoring, and an algorithm that identifies patients at risk of opioid use disorder. The platform runs continuously rather than only at the moment of ordering, and delivers into existing systems through vendor agnostic APIs, an athenahealth Marketplace listing and, at Ballad Health from 2024, natively inside an Epic pharmacy workflow. MedAware is unusual in this index for the independence of its evidence base, which was produced largely by investigators at Brigham and Women's Hospital and Harvard Medical School and published in JAMIA and the Joint Commission Journal on Quality and Patient Safety, and equally unusual for how little it publishes about its own compliance, security and governance posture.

Drug and toxicology reference from Merative, the company formed in June 2022 when Francisco Partners acquired the Watson Health assets from IBM. Headquartered in Ann Arbor, Michigan; Merative chief executive Gerry McCarthy, with Sonika Mathur as general manager for Micromedex. Content is curated by clinical experts from primary literature with in line referencing and daily updates, and is used in more than 80 countries by providers, poison control centres, government departments, universities, pharmaceutical organisations and health plans. The artificial intelligence layer is search. Released 23 September 2025, it lets a clinician ask natural language questions about drug information including interactions and intravenous administration, and returns answers drawn from Micromedex content with a citation on every result that opens the underlying source in one click. Interface affordances include suggested searches and follow up prompts. The company describes the capability as clinically validated. Scoping note, because the boundary matters for this index. DynaMedex is a separate joint product combining this drug content with EBSCO's DynaMed disease content, and it is graded on the DynaMed record rather than here; a December 2025 agreement additionally routes Micromedex dosing and medication safety content into that product's generative layer. This record covers Micromedex itself. Two facts sit outside what a reference product normally carries and both are on the record. Micromedex is recognised as a drug compendium under United States federal law, which makes its content a determinant of coverage for certain off label uses rather than merely a guide to them. And in a separate arrangement the company has licensed a subset of its drug content into a consumer artificial intelligence answer engine as a premium source. Named number one for point of care drug reference in the 2026 Best in KLAS report, for the second time.

Medication intelligence platform whose ControlCheck product, formerly Bluesight for Controlled Substances, is the market share leader in drug diversion detection. Founded 2011 as Kit Check, rebranded to Bluesight in December 2022, based in Alexandria, Virginia, led by co founder and chief executive Kevin MacDonald and backed by Thoma Bravo. The diversion product connects data from automated dispensing cabinets, electronic medical records and other systems to deliver a 100 percent audit of dispense, administration, waste and return records for controlled substances, flagging discrepancies for review so pharmacy staff investigate real issues rather than manually reconciling records. The stated technical approach is notably specific: unsupervised machine learning with continuous learning, identifying anomalous patterns in clinician behaviour. The company's own explanation of why is the clearest articulation of the AI necessity argument in this category, and it is candid about what it replaces: simple statistics such as standard deviations and averages have proven inadequate against diverters who have become adept at covering their tracks, because diversion patterns are often visible only when many variables are compared simultaneously and evaluated against other patterns. Reported Best in KLAS three years running, with more than 100 million medication transactions tracked and over 1,000 US and Canadian hospitals using Bluesight solutions. Deployment is deliberately low friction: the platform runs on a HIPAA-compliant cloud, leverages existing reports and multiple data delivery options rather than requiring complex integrations, and one health system implemented across 10 hospitals in a reported 33 days with minimal IT involvement. Updated 29 August 2026. The company has grown substantially by acquisition and has folded each acquired brand into its own product line rather than operating it as a standing brand: Medacist in 2023, Sectyr in 2024, and Protenus in January 2025. The patient privacy monitoring product now sold as PrivacyPro is the former Protenus platform, and Bluesight's own announcements refer to it as previously Protenus. In the 2025 Best in KLAS report ControlCheck scored 86.1 in the drug diversion monitoring category and the patient privacy product scored 94.3, among the highest scores recorded in that ranking. The suite now runs to six products: ControlCheck, PrivacyPro, KitCheck for radio frequency identification kit and tray inventory, CostCheck for drug spend, 340BCheck for covered entity compliance which was rebuilt on Sectyr technology and relaunched in April 2026 with a 100 percent transaction audit, and ShortageCheck for shortage forecasting. Prism Assistant, the first product on a new artificial intelligence platform, arrived in 2026 and carries no located governance or model disclosure. Indexed in cybersecurity for the diversion and privacy products specifically, applying the product-scoping rule: the inventory, spend and 340B products are pharmacy operations tools rather than security. Medication safety and prescribing is carried as a secondary category because ControlCheck is a direct comparator to the diversion analytics sold inside the BD Pyxis and Omnicell dispensing estates, and a buyer comparing those three should find all of them.